How to optimize the evaluation and use of antibiotics in neonates

Early Human Development

Volumn 90, Issue SUPPL.1, 2014, Pages

  Van den Anker, Johannes N ^a,b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Aminoglycosides; Infectious diseases; Neonates; Vancomycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLOXACILLIN; FLUCLOXACILLIN; GENTAMICIN; PENICILLIN G; TOBRAMYCIN; VANCOMYCIN; AMINOGLYCOSIDE;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; HYDROLYSIS; KIDNEY CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; NONHUMAN; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS; EVALUATION STUDY; NEWBORN; SEPSIS; STANDARDS;

AMINOGLYCOSIDES; EVALUATION STUDIES AS TOPIC; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; SEPSIS; VANCOMYCIN;

EID: 84897555890     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/S0378-3782(14)70004-0     Document Type: Review

References (8)

1. Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, Eunice Kennedy Shriver National Institute of Child Health, Human Development Neonatal Research Network, et al. Early onset sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics 2011, 127:817-826.
2. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-onset sepsis in very low birth weight neonates: a report from the national institute of child health and human development neonatal research network. J Pediatr 1996, 129:63-71.
3. Begg EJ, Barclay ML Aminoglycosides-50 years on. Br J Clin Pharmacol 1995, 39:597.
4. Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Meropenem Study Team, et al. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012, 55:1495-1502.
5. De Hoog M, Mouton JW, Schoemaker RC, Verduin CM, van den Anker JN Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002, 71:349-358.
6. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2013 Sept 25, [Epub ahead of print].
7. De Hoog M, Mouton JW, van den Anker JN Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004, 43:417-440.
8. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012, 67:17-24.